This Week’s Biotech Highlights
A “Round 2” edition of biotech highlights:
- Round 1 of this week’s IPOs (yep, that’s IPO with an “s”, as in more than one) was a draw, with shares of Cumberland ending flat on the day; but Round 2 — Emdeon’s offering the next day — was a knock-out, leading some (ok, me) to suggest the markets may be opening up to the idea of biopharma offerings.
- Round 2 of Amgen’s study showed that genetic differences really do correlate with response to their medicine — Vectibix — in the treatment of colorectal cancer. Score this one for personalized medicine


